Inovio Pharmaceuticals, Inc. (INO) Stock
INO Key Statistics
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
CEO: Jacqueline E. Shea. Company website
INO — Frequently Asked Questions
What is the INO stock price today?
Inovio Pharmaceuticals, Inc. (INO) trades at $0.84, up 5.48% on the day, as of Oct 23, 2026 00:41 UTC.
What is Inovio Pharmaceuticals, Inc.'s market cap?
Inovio Pharmaceuticals, Inc. has a market capitalisation of $57.96M, calculated from the live INO share price and shares outstanding.
What is the P/E ratio of INO?
INO has no meaningful price-to-earnings ratio: Inovio Pharmaceuticals, Inc. lost $1.17 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Inovio Pharmaceuticals, Inc. make?
Inovio Pharmaceuticals, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for INO?
INO has traded between $0.56 and $2.72 over the past 52 weeks, and the last price is 69.2% below that high.
Is Inovio Pharmaceuticals, Inc. profitable?
Yes. Inovio Pharmaceuticals, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for INO?
Wall Street analysts rate INO Buy, with an average price target of $2.75, 227.8% above the current price.
What sector is Inovio Pharmaceuticals, Inc. in?
Inovio Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Inovio Pharmaceuticals, Inc.?
Jacqueline E. Shea is the chief executive of Inovio Pharmaceuticals, Inc., which employs 112 people.
Where can I track INO in real time?
QFI Terminal shows INO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See INO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open INO in Terminal See plans